Shire plc Annual review 2008

Shire
  • Home
  • This year’s highlights
  • Patients & products
  • Shire’s business model
  • Corporate responsibility
  • Our team
  • Financial summary
  • Downloads
  • Additional info
  • Home
  • This year’s highlights
    • This year’s highlights
    • Chairman’s review
    • Chief Executive’s review
    • R&D Projects
  • Patients & products
    • VYVANSE
    • LIALDA / MEZAVANT XL
    • FOSRENOL
    • ELAPRASE
    • REPLAGAL
    • FIRAZYR
  • Shire’s business model
    • Strategy
    • Putting it into practice
    • Focus on the science - Specialty Pharma
    • Focus on the science - HGT
    • From science to sales
    • Looking to the future
    • Shire tomorrow
  • Corporate responsibility
    • Corporate Responsibility at Shire
    • Employees, customers, suppliers, communities and environment
  • Our team
    • Board of Directors
    • Leadership Team
  • Financial summary
    • Financial Review
    • Summary Consolidated Balance Sheets
    • Summary Consolidated Statements of Operations
    • Summary Consolidated Statements of Cash Flows
    • Notes to the Summary Financial Information
    • Summary Directors' Remuneration Report
  • Downloads
  • Additional info
    • Shire head offices and main operating locations
    • Shareholder information
    • Cautionary statements
    • Glossary of terms
© Copyright Shire 2009. All rights reserved
  • Corporate website
  • Disclaimer
  • Legal notice
  • Sitemap